UCB Biopharma SRL
Clinical trials sponsored by UCB Biopharma SRL, explained in plain language.
Now part of
UCB S.A.
UCB
EURONEXT BRUSSELS
Belgian biopharmaceutical company focused on neurology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaler aims to halt seizures in seconds Results expected Sep 2026 (estimated)
- New drug hope for kids with rare Muscle-Weakening disease Results expected Oct 2026 (estimated)
- Promising drug for kids with rare muscle disease moves to next phase Results expected Nov 2026 (estimated)
- New drug UCB5285 gets first human safety check Results expected Dec 2026 (estimated)
- New hope for teens with severe skin disease: drug trial launches Results expected Dec 2026 (estimated)